Comparing study features of anti-TNF trials in pSpA
| CRESPA trial13 55 | ABILITY-2 trial33 | Paramarta et al3554 | |
|---|---|---|---|
| Inclusion criteria | ASAS classification criteria + rheumatologist diagnosis | ASAS classification criteria + no prior psoriasis, PsA or AS | ESSG or Amor criteria + no AS or PsA |
| Multicenter study | No | Yes | No |
| Anti-TNF-blocking agent | Golimumab | Adalimumab | Adalimumab |
| Number of included patients | 60 | 165 | 40 |
| Symptom duration (mean ± SD years) | 5.2 weeks ±2.8 vs 4.4 weeks ±2.0 | 6.6 years ±6.3 vs 7.7 years ±7.9 | 7.9 years ±9.3 vs 6.7 years ±6.2 |
| Primary end point % patients in clinical remission at w24 % patient PSpARC40 response at w12 PGA of disease activity | Absence of arthritis, dactylitis and enthesitis at w24 75% vs 20% (p<0.001) 57.5% vs 20% (p=0.0069) −50.0 vs −20.0 (p=0.0015) | PSpARC40 response criteria at w12 ND 39% vs 20% (p=0.006) −27.5 vs −16.4 (p=0.003) | PGA of disease activity ND ND −31.0 vs −5.9 (p=0.001) |
| Withdrawal strategy Relapse rate after discontinuation | Yes 47% | No | Yes 73% |
AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; ESSG criteria, European Spondylitis Study Group criteria; PSpARC40 response criteria, peripheral spondyloarthritis 40% response criteria.